On the production of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) by human neutrophils
- 30 March 2006
- journal article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 79 (6) , 1140-1149
- https://doi.org/10.1189/jlb.1005558
Abstract
Contrary to their traditional characterization as terminally differentiated effectors of inflammation, neutrophils are remarkably versatile cells. Indeed, their capacity to change phenotype under specific circumstances, their active involvement in the regulation and resolution of inflammation, their response to a wide variety of cytokines and chemotactic molecules, and their regulatory role in angiogenesis and tumor fate have made it clear that they represent far more than “short-lived cells devoid of transcriptional activities, that only release preformed mediators and kill pathogens”. The multiple and amazing functional capacities of this cell type are also illustrated by the fact that the neutrophil may function as an important source of cytokines, at levels comparable with and in some cases, higher than those made by other leukocytes. To date, the families of cytokines, which in vitro or in vivo have been convincingly reported as being produced by neutrophils, include proinflammatory/anti-inflammatory cytokines, immunoregulatory cytokines, chemokines, angiogenic/fibrogenic factors, and tumor necrosis factor (TNF) superfamily members. The latter molecules are multifaceted cytokines whose integrated actions not only influence the development, homeostasis, and adaptive responses of many cells and tissue types but are also implicated in the antitumoral response. The recent findings that neutrophils produce in a finely regulated manner a TNF superfamily member involved in tumor cell killing and autoimmunity, namely TNF-related apoptosis-inducing ligand, open an additional perspective to exploit neutrophils for novel roles in anticancer responses and modulation of autoimmune diseases.Keywords
Funding Information
- Ministero dell’Istruzione
- dell’Università e della Ricerca (PRIN 2003, FIRB, 60%)
- Fondazione Cassa di Risparmio di Verona-Vicenza-Ancona e Belluno
- Associazione Italiana per la Ricerca sul Cancro
This publication has 69 references indexed in Scilit:
- Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon‐α in human myeloma cellsFEBS Letters, 2005
- Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2005
- Absence of Gene Mutation in TRAIL Receptor 1 (TRAIL-R1) and TRAIL Receptor 2 (TRAIL-R2) in Chronic Myelogenous Leukemia and Myelodysplastic Syndrome, and Analysis of mRNA Expressions of TRAIL and TRAIL-Related Genes in Chronic Myelogenous LeukemiaActa Haematologica, 2005
- Death to the bad guys: Targeting cancer via Apo2L/TRAILApoptosis, 2005
- Monocytes Stimulated with Group B Streptococci or Interferons Release Tumour Necrosis Factor‐Related Apoptosis‐Inducing LigandScandinavian Journal of Immunology, 2004
- Neutrophil-Derived TNF-Related Apoptosis-Inducing Ligand (TRAIL)Cancer Research, 2004
- Expression of MHC Class II Antigen and Coreceptor Molecules in Polymorphonuclear NeutrophilsPublished by S. Karger AG ,2003
- T HELPER 1/2 LYMPHOCYTE URINARY CYTOKINE PROFILES IN RESPONDING AND NONRESPONDING PATIENTS AFTER 1 AND 2 COURSES OF BACILLUS CALMETTE-GUERIN FOR SUPERFICIAL BLADDER CANCERJournal of Urology, 2001
- Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAILThe Journal of Experimental Medicine, 1999
- Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cellsEuropean Journal of Immunology, 1998